De novo Biotherapeutics
Seoul
About De novo Biotherapeutics
De novo Biotherapeutics is a biotechnology company developing mRNA-encoded antibodies and NK cell-engaging antibodies for cancer treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $5.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2022)
- Website: denovobio.co.krenindex.php
- Phone: 02-734-3305
Industries & Categories
Biopharma, Biotechnology, Oncology
Canonical: https://fsome.com/organization/de-novo-biotherapeutics-23595 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.